The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picks4basebio Plc Regulatory News (4BB)

Share Price Information for 4basebio Plc (4BB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,080.00
Bid: 1,060.00
Ask: 1,100.00
Change: 0.00 (0.00%)
Spread: 40.00 (3.774%)
Open: 1,080.00
High: 1,080.00
Low: 1,080.00
Prev. Close: 1,080.00
4BB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Feb 2021 17:35

4basebio UK Societas - Holding(s) in Company

4basebio UK Societas - Holding(s) in Company

PR Newswire

London, February 19

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:4basebio UK Societas
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rightsx
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
NameWilhelm K. T. Zours
City and country of registered office (if applicable)Heidelberg, Germany
4. Full name of shareholder(s) (if different from 3.)v
NameDELPHI Unternehmensberatung Aktiengesellschaft
City and country of registered office (if applicable)Heidelberg, Germany
5. Date on which the threshold was crossed or reachedvi:17/02/2021
6. Date on which issuer notified (DD/MM/YYYY):17/02/2021
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached20.27%-20.27%12,317,473
Position of previous notification (if applicable)---

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)Number of voting rightsix% of voting rights
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BLD8ZL39-2,496,933-20.27%
SUBTOTAL 8. A2,496,93320.27%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration datexExercise/ Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights
N/A
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration datexExercise/ Conversion Period xiPhysical or cash settlementxiiNumber of voting rights% of voting rights
N/A
SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)X
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Wilhelm K. T. Zours
DELPHI Unternehmensberatung Aktiengesellschaft5.18%5.18%
Deutsche Balaton Aktiengesellschaft4.11%4.11%
Sparta AG10.97%10.97%
10. In case of proxy voting, please identify:
Name of the proxy holderN/A
The number and % of voting rights heldN/A
The date until which the voting rights will be heldN/A
11. Additional informationxvi
Wilhelm K. T. Zours controls circa 48% of 4basebio AG, who in turn holds 30% of the voting rights of 4basebio UK Societas.

Place of completionHeidelberg, Germany
Date of completion19/02/2021
12
Date   Source Headline
10th Apr 20247:00 amPRN4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client's vaccine program
21st Mar 20247:00 amPRN4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine
1st Mar 20247:00 amPRN4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI's tender process for supplying its RNA Centre of Excellence
6th Feb 20247:01 amPRNHolding(s) in Company
6th Feb 20247:01 amPRNHolding(s) in Company
6th Feb 20247:01 amPRNHolding(s) in Company
6th Feb 20247:01 amPRNHolding(s) in Company
6th Feb 20247:00 amPRNExercise of Options
5th Feb 20247:01 amPRNHolding(s) in Company
5th Feb 20247:01 amPRNHolding(s) in Company
5th Feb 20247:01 amPRNHolding(s) in Company
5th Feb 20247:00 amPRNDirectors' Dealings
2nd Feb 20247:00 amPRNLong-Term Incentive Plan and Exercise of Options
21st Sep 20237:00 amPRNHalf-year Report
1st Aug 20237:00 amPRNGrant received from the Bill and Melinda Gates Foundation
27th Sep 20229:05 amRNSSecond Price Monitoring Extn
27th Sep 20229:00 amRNSPrice Monitoring Extension
6th May 20222:00 pmRNSPrice Monitoring Extension
23rd Mar 20227:00 amPRNRapidly Produced Customisable Synthetic DNA
15th Mar 20224:41 pmRNSSecond Price Monitoring Extn
15th Mar 20224:35 pmRNSPrice Monitoring Extension
15th Mar 20222:05 pmRNSSecond Price Monitoring Extn
15th Mar 20222:01 pmRNSPrice Monitoring Extension
15th Mar 202211:00 amRNSPrice Monitoring Extension
15th Mar 20229:00 amRNSPrice Monitoring Extension
8th Mar 20229:00 amRNSPrice Monitoring Extension
15th Feb 20227:00 amPRNDNA manufacturing update
18th Jan 20227:00 amPRNStrategic Research Collaboration
20th Dec 202112:49 pmPRNDirector/PDMR Shareholding
13th Dec 20213:55 pmPRNDirector/PDMR Shareholding
23rd Nov 20217:00 amPRNJoint Development Agreement with Leucid Bio
30th Sep 20217:00 amPRNHalf-year Report
28th Sep 20217:00 amPRNDevelopment of GMP Manufacturing Capacity
4th Aug 20214:40 pmRNSSecond Price Monitoring Extn
4th Aug 20214:35 pmRNSPrice Monitoring Extension
23rd Jul 20213:39 pmPRNFurther re Conversion to UK PLC
21st Jul 20217:00 amPRNConversion to UK PLC
1st Jul 20214:09 pmPRNDirector/PDMR Shareholding
30th Jun 202112:50 pmPRNResult of AGM
22nd Jun 20217:00 amPRNApplication filed for protected linearised synthetic DNA
18th Jun 20217:00 amPRNAnnual General Meeting 2021
4th Jun 20217:00 amPRNNotice of AGM and Posting of Accounts
3rd Jun 20217:00 amPRNFinal Results
27th Apr 20217:00 amPRNEvaluation licence for muscular dystrophy vector
26th Feb 20217:00 amPRNDirector/PDMR Shareholding
25th Feb 20219:05 amRNSSecond Price Monitoring Extn
25th Feb 20219:00 amRNSPrice Monitoring Extension
22nd Feb 202111:00 amRNSPrice Monitoring Extension
22nd Feb 20219:31 amPRNHolding(s) in Company
19th Feb 20215:35 pmPRNHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.